List of Tables
Table 1. Global AAV Vector-Based Gene Therapy Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global AAV Vector-Based Gene Therapy Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global AAV Vector-Based Gene Therapy Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global AAV Vector-Based Gene Therapy Drugs Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global AAV Vector-Based Gene Therapy Drugs Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global AAV Vector-Based Gene Therapy Drugs Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global AAV Vector-Based Gene Therapy Drugs Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global AAV Vector-Based Gene Therapy Drugs by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in AAV Vector-Based Gene Therapy Drugs as of 2024)
Table 11. Global AAV Vector-Based Gene Therapy Drugs Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global AAV Vector-Based Gene Therapy Drugs Companies Headquarters
Table 13. Global AAV Vector-Based Gene Therapy Drugs Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global AAV Vector-Based Gene Therapy Drugs Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global AAV Vector-Based Gene Therapy Drugs Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global AAV Vector-Based Gene Therapy Drugs Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global AAV Vector-Based Gene Therapy Drugs Revenue by Application (2026-2031) & (US$ Million)
Table 21. AAV Vector-Based Gene Therapy Drugs High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America AAV Vector-Based Gene Therapy Drugs Growth Accelerators and Market Barriers
Table 25. North America AAV Vector-Based Gene Therapy Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe AAV Vector-Based Gene Therapy Drugs Growth Accelerators and Market Barriers
Table 27. Europe AAV Vector-Based Gene Therapy Drugs Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific AAV Vector-Based Gene Therapy Drugs Growth Accelerators and Market Barriers
Table 29. Asia-Pacific AAV Vector-Based Gene Therapy Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America AAV Vector-Based Gene Therapy Drugs Investment Opportunities and Key Challenges
Table 31. Central and South America AAV Vector-Based Gene Therapy Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa AAV Vector-Based Gene Therapy Drugs Investment Opportunities and Key Challenges
Table 33. Middle East and Africa AAV Vector-Based Gene Therapy Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. uniQure Corporation Information
Table 35. uniQure Description and Major Businesses
Table 36. uniQure Product Features and Attributes
Table 37. uniQure Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. uniQure Revenue Proportion by Product in 2024
Table 39. uniQure Revenue Proportion by Application in 2024
Table 40. uniQure Revenue Proportion by Geographic Area in 2024
Table 41. uniQure AAV Vector-Based Gene Therapy Drugs SWOT Analysis
Table 42. uniQure Recent Developments
Table 43. Spark Therapeutics Corporation Information
Table 44. Spark Therapeutics Description and Major Businesses
Table 45. Spark Therapeutics Product Features and Attributes
Table 46. Spark Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Spark Therapeutics Revenue Proportion by Product in 2024
Table 48. Spark Therapeutics Revenue Proportion by Application in 2024
Table 49. Spark Therapeutics Revenue Proportion by Geographic Area in 2024
Table 50. Spark Therapeutics AAV Vector-Based Gene Therapy Drugs SWOT Analysis
Table 51. Spark Therapeutics Recent Developments
Table 52. AveXis (Novartis) Corporation Information
Table 53. AveXis (Novartis) Description and Major Businesses
Table 54. AveXis (Novartis) Product Features and Attributes
Table 55. AveXis (Novartis) Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. AveXis (Novartis) Revenue Proportion by Product in 2024
Table 57. AveXis (Novartis) Revenue Proportion by Application in 2024
Table 58. AveXis (Novartis) Revenue Proportion by Geographic Area in 2024
Table 59. AveXis (Novartis) AAV Vector-Based Gene Therapy Drugs SWOT Analysis
Table 60. AveXis (Novartis) Recent Developments
Table 61. PTC Therapeutics Corporation Information
Table 62. PTC Therapeutics Description and Major Businesses
Table 63. PTC Therapeutics Product Features and Attributes
Table 64. PTC Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. PTC Therapeutics Revenue Proportion by Product in 2024
Table 66. PTC Therapeutics Revenue Proportion by Application in 2024
Table 67. PTC Therapeutics Revenue Proportion by Geographic Area in 2024
Table 68. PTC Therapeutics AAV Vector-Based Gene Therapy Drugs SWOT Analysis
Table 69. PTC Therapeutics Recent Developments
Table 70. BioMarin Corporation Information
Table 71. BioMarin Description and Major Businesses
Table 72. BioMarin Product Features and Attributes
Table 73. BioMarin Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. BioMarin Revenue Proportion by Product in 2024
Table 75. BioMarin Revenue Proportion by Application in 2024
Table 76. BioMarin Revenue Proportion by Geographic Area in 2024
Table 77. BioMarin AAV Vector-Based Gene Therapy Drugs SWOT Analysis
Table 78. BioMarin Recent Developments
Table 79. Sarepta Therapeutics Corporation Information
Table 80. Sarepta Therapeutics Description and Major Businesses
Table 81. Sarepta Therapeutics Product Features and Attributes
Table 82. Sarepta Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Sarepta Therapeutics Recent Developments
Table 84. Roche Corporation Information
Table 85. Roche Description and Major Businesses
Table 86. Roche Product Features and Attributes
Table 87. Roche Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Roche Recent Developments
Table 89. Pfizer Corporation Information
Table 90. Pfizer Description and Major Businesses
Table 91. Pfizer Product Features and Attributes
Table 92. Pfizer Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Pfizer Recent Developments
Table 94. Raw Materials Key Suppliers
Table 95. Distributors List
Table 96. Market Trends and Market Evolution
Table 97. Market Drivers and Opportunities
Table 98. Market Challenges, Risks, and Restraints
Table 99. Research Programs/Design for This Report
Table 100. Key Data Information from Secondary Sources
Table 101. Key Data Information from Primary Sources
List of Figures
Figure 1. AAV Vector-Based Gene Therapy Drugs Product Picture
Figure 2. Global AAV Vector-Based Gene Therapy Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. AAV2 Vector Product Picture
Figure 4. AAV5 Vector Product Picture
Figure 5. Others Product Picture
Figure 6. Global AAV Vector-Based Gene Therapy Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Hospital
Figure 8. Diagnostic and Testing Laboratories
Figure 9. Academic and Research Organizations
Figure 10. Others
Figure 11. AAV Vector-Based Gene Therapy Drugs Report Years Considered
Figure 12. Global AAV Vector-Based Gene Therapy Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global AAV Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 14. Global AAV Vector-Based Gene Therapy Drugs Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 15. Global AAV Vector-Based Gene Therapy Drugs Revenue Market Share by Region (2020-2031)
Figure 16. Global AAV Vector-Based Gene Therapy Drugs Revenue Market Share Ranking (2024)
Figure 17. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 18. AAV2 Vector Revenue Market Share by Player in 2024
Figure 19. AAV5 Vector Revenue Market Share by Player in 2024
Figure 20. Others Revenue Market Share by Player in 2024
Figure 21. Global AAV Vector-Based Gene Therapy Drugs Revenue Market Share by Type (2020-2031)
Figure 22. Global AAV Vector-Based Gene Therapy Drugs Revenue Market Share by Application (2020-2031)
Figure 23. North America AAV Vector-Based Gene Therapy Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 24. North America Top 5 Players AAV Vector-Based Gene Therapy Drugs Revenue (US$ Million) in 2024
Figure 25. North America AAV Vector-Based Gene Therapy Drugs Revenue (US$ Million) by Type (2020 - 2031)
Figure 26. North America AAV Vector-Based Gene Therapy Drugs Revenue (US$ Million) by Application (2020-2031)
Figure 27. US AAV Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 28. Canada AAV Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 29. Mexico AAV Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 30. Europe AAV Vector-Based Gene Therapy Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 31. Europe Top 5 Players AAV Vector-Based Gene Therapy Drugs Revenue (US$ Million) in 2024
Figure 32. Europe AAV Vector-Based Gene Therapy Drugs Revenue (US$ Million) by Type (2020-2031)
Figure 33. Europe AAV Vector-Based Gene Therapy Drugs Revenue (US$ Million) by Application (2020-2031)
Figure 34. Germany AAV Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 35. France AAV Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 36. U.K. AAV Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 37. Italy AAV Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 38. Russia AAV Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 39. Asia-Pacific AAV Vector-Based Gene Therapy Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 40. Asia-Pacific Top 8 Players AAV Vector-Based Gene Therapy Drugs Revenue (US$ Million) in 2024
Figure 41. Asia-Pacific AAV Vector-Based Gene Therapy Drugs Revenue (US$ Million) by Type (2020-2031)
Figure 42. Asia-Pacific AAV Vector-Based Gene Therapy Drugs Revenue (US$ Million) by Application (2020-2031)
Figure 43. Indonesia AAV Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 44. Japan AAV Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 45. South Korea AAV Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 46. Australia AAV Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 47. India AAV Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 48. Indonesia AAV Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 49. Vietnam AAV Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 50. Malaysia AAV Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 51. Philippines AAV Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 52. Singapore AAV Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 53. Central and South America AAV Vector-Based Gene Therapy Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 54. Central and South America Top 5 Players AAV Vector-Based Gene Therapy Drugs Revenue (US$ Million) in 2024
Figure 55. Central and South America AAV Vector-Based Gene Therapy Drugs Revenue (US$ Million) by Type (2020-2031)
Figure 56. Central and South America AAV Vector-Based Gene Therapy Drugs Revenue (US$ Million) by Application (2020-2031)
Figure 57. Brazil AAV Vector-Based Gene Therapy Drugs Revenue (2020-2025) & (US$ Million)
Figure 58. Argentina AAV Vector-Based Gene Therapy Drugs Revenue (2020-2025) & (US$ Million)
Figure 59. Middle East and Africa AAV Vector-Based Gene Therapy Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 60. Middle East and Africa Top 5 Players AAV Vector-Based Gene Therapy Drugs Revenue (US$ Million) in 2024
Figure 61. South America AAV Vector-Based Gene Therapy Drugs Revenue (US$ Million) by Type (2020-2031)
Figure 62. Middle East and Africa AAV Vector-Based Gene Therapy Drugs Revenue (US$ Million) by Application (2020-2031)
Figure 63. GCC Countries AAV Vector-Based Gene Therapy Drugs Revenue (2020-2025) & (US$ Million)
Figure 64. Israel AAV Vector-Based Gene Therapy Drugs Revenue (2020-2025) & (US$ Million)
Figure 65. Egypt AAV Vector-Based Gene Therapy Drugs Revenue (2020-2025) & (US$ Million)
Figure 66. South Africa AAV Vector-Based Gene Therapy Drugs Revenue (2020-2025) & (US$ Million)
Figure 67. AAV Vector-Based Gene Therapy Drugs Industry Chain Mapping
Figure 68. Channels of Distribution (Direct Vs Distribution)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
